Dapagliflozin 10mg
Dapagliflozin 10mg is a pharmaceutical drug with 27 clinical trials. Currently 3 active trials ongoing. Historical success rate of 82.4%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
5
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.8%
14 of 18 finished
22.2%
4 ended early
3
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Clinical Trials (27)
The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease
The Effects of Dapagliflozin in Normal Clinical Practice in T2D
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction
Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation
DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27